DEF: InnovAge Sets 2025 Annual Meeting, Board Elections & Auditor Ratification

InnovAge Holding Corp. announces its virtual 2025 Annual Meeting of Stockholders to elect three Class II directors and ratify Deloitte & Touche LLP as its independent auditor.

Summary

• The Annual Meeting of Stockholders will be held virtually on Thursday, December 4, 2025, at 9:00 a.m. Eastern Time.
• Stockholders will vote on the election of three director nominees (James G. Carlson, Teresa Sparks, and Richard Zoretic) to serve as Class II directors until the 2028 Annual Meeting.
• Stockholders will also vote on the ratification of Deloitte & Touche LLP as the company's independent registered public accounting firm for the fiscal year ending June 30, 2026.
• The record date for stockholders entitled to vote is October 14, 2025, with 135,681,431 shares of common stock outstanding.
• The Board of Directors recommends voting FOR all director nominees and FOR the ratification of Deloitte & Touche LLP.
• Executive compensation for the fiscal year ended June 30, 2025, included base salaries of $770,000 for CEO Patrick Blair, $317,575 for President and COO Michael Scarbrough, and $457,000 for Chief Legal Officer Nicole DAmato.
• Annual cash bonuses for FY2025 were $770,000 for Patrick Blair, $364,000 for Michael Scarbrough, and $302,000 for Nicole DAmato.
• Michael Scarbrough, President and Chief Operating Officer, will depart effective November 28, 2025.
• InnovAge operates as a 'controlled company' under Nasdaq listing standards, allowing it to rely on certain corporate governance exemptions.
• Audit fees paid to Deloitte & Touche LLP were $1,230,708 for FY2025 and $1,152,916 for FY2024, with audit-related fees of $49,816 for FY2025 and $46,787 for FY2024.

Sentiment

Score: 7

Explanation: The filing is a standard definitive proxy statement for an annual meeting, outlining routine governance matters such as director elections and auditor ratification. Positives include a structured approach to risk oversight, a diverse board, and the implementation of a clawback policy. The 'controlled company' status and the upcoming departure of the President and COO are noted but do not significantly alter the overall neutral to slightly positive sentiment for a routine governance document.

Positives

• The Board's composition is designed to include individuals with diverse professional expertise, skills, viewpoints, and backgrounds, including three women and one male director with disabilities.
• The company maintains a separated Chair and Chief Executive Officer leadership structure, with an independent Chair (James G. Carlson) providing strategic guidance and oversight, enhancing accountability.
• A robust enterprise-wide risk management approach is in place, with primary oversight of specific risks delegated to the Audit, Compensation and Nominating, and Quality and Compliance Committees.
• The Board is actively involved in monitoring new threats and risks, and dictates strategy for organic and inorganic growth, including de novo centers, participant enrollment, joint ventures, and acquisitions.
• A clawback policy, compliant with Nasdaq rules, was adopted effective September 7, 2023, requiring executives to reimburse incentive-based compensation in case of accounting restatements.
• An Insider Trading Policy prohibits employees, directors, and officers from engaging in hedging or pledging company securities, aligning their interests with long-term stockholder value.

Negatives

• As a 'controlled company' under Nasdaq rules, InnovAge relies on exemptions from certain corporate governance requirements, potentially affording stockholders fewer protections than companies subject to all Nasdaq standards.
• James G. Carlson, Chair of the Board, attended 71% of the aggregate Board and committee meetings during fiscal year 2025, which is below the company's expectation of at least 75% attendance.
• Administrative errors led to untimely Section 16(a) reports for James G. Carlson (one transaction) and Nicole DAmato (one transaction) during the fiscal year ended June 30, 2025.
• Michael Scarbrough, President and Chief Operating Officer, will be departing the company effective November 28, 2025.

Risks

• Challenges associated with achieving growth while maintaining high-quality service.
• Exposure to legal and regulatory risks inherent in the healthcare industry.
• Potential privacy and cybersecurity risks.
• Financial, tax, and audit-related risks.
• The company's 'controlled company' status and Director Nomination Agreement grant significant influence to Principal Shareholders over board composition and corporate governance.
• Ongoing legal actions and proceedings that the company currently faces.
• Risks associated with routine and non-routine governmental inspections, reviews, and audits.

Future Outlook

The Board is focused on responsible growth, joint ventures, and regulatory compliance. It is actively involved in monitoring new threats and risks, and dictates strategy for organic and inorganic growth, including opening de novo centers, growing participant enrollment, and pursuing joint ventures (e.g., Tampa PACE center with Tampa General Health in FY2025) or acquisition opportunities (e.g., two PACE centers in California from ConcertoCare in FY2024).

Management Comments

• We are pleased to invite you to attend our Annual Meeting of Stockholders of InnovAge Holding Corp.
• Your vote is important. Whether or not you plan to attend the virtual Annual Meeting, we urge you to vote.
• The Board believes that in order for our Board to effectively guide us to long-term sustainable, dependable performance, it should be composed of individuals with sophistication and experience in the many disciplines that impact our business.
• The Board believes that not having the Chief Executive Officer be a member of the Board and separating the roles of Chair and Chief Executive Officer is the most effective leadership structure because it allows Mr. Blair to focus on the management of the Company, day-to-day operations and engaging with external stakeholders, including regulators.
• Our Board appreciates the evolving nature of our business and industry and is actively involved with monitoring new threats and risks as they emerge.

Industry Context

InnovAge operates within the highly regulated U.S. healthcare industry, specifically focusing on programs like PACE (Program of All-Inclusive Care for the Elderly), Medicare, and Medicaid. The company's board and executive team possess extensive experience in managed healthcare, physician-led services, post-acute care, senior living, and public health insurance marketplaces, reflecting the complex regulatory and operational landscape of the sector. The emphasis on healthcare regulatory issues, government relations, and quality of care is critical given the nature of its business.

Comparison to Industry Standards

• InnovAge's status as a 'controlled company' under Nasdaq listing standards allows it to deviate from certain corporate governance requirements, such as having a majority independent board or fully independent compensation and nominations committees. This contrasts with the governance structures of many publicly traded companies that are not controlled.
• The board's composition, with members possessing expertise in healthcare regulatory issues, accounting, risk management, and government relations, aligns with the specialized needs of a company operating in the complex healthcare sector.
• The adoption of a clawback policy compliant with Nasdaq rules demonstrates adherence to evolving corporate governance standards aimed at executive accountability, aligning with best practices for public companies.

Management Changes

Corporate Governance

Legal Proceedings

• The company is currently facing various legal actions and proceedings, and the Board is focused on the company's response and legal strategy.

Related Party Transactions

• Director Nomination Agreement: Provides Principal Shareholders the right to designate nominees for election to the Board.
• Registration Rights Agreement: Entitles Principal Shareholders to request registration of their shares and participate in certain registered offerings, with the company covering certain expenses.
• Indemnification of Officers and Directors: The company has entered into indemnification agreements with executive officers and directors, providing contractual rights to indemnification, expense advancement, and reimbursement.

Stakeholder Impact

• Shareholders: Will participate in key governance decisions (director elections, auditor ratification) and are impacted by the 'controlled company' status and Principal Shareholders' influence.
• Employees: Subject to insider trading and clawback policies, and their compensation structure is detailed.
• Management: Executive compensation, severance benefits, and equity awards are outlined, and the CEO's role is distinct from the Board Chair.
• Customers/Participants (PACE): The Quality and Compliance Committee's oversight of healthcare quality and compliance directly impacts the services provided to participants.
• Regulators: The company's operations are subject to significant regulatory scrutiny, and the Board's focus on compliance and engagement with authorities is crucial.

Next Steps

• Stockholders are urged to vote on director nominees and auditor ratification by December 3, 2025, for Internet/phone proxies, or at the Annual Meeting on December 4, 2025.
• Final voting results will be published in a Current Report on Form 8-K filed with the SEC within four business days of the Annual Meeting.
• Stockholder proposals for inclusion in the company's proxy statement for the 2026 annual meeting must be submitted by email no later than June 25, 2026.
• Stockholders wishing to make a director nomination or bring a proposal before the 2026 annual meeting (other than pursuant to SEC Rule 14a-8) must deliver written notice between August 6, 2026, and September 4, 2026.
• Stockholders intending to solicit proxies in support of director nominees (under Rule 14a-19) for the 2026 annual meeting must provide written notice by October 5, 2026.

Key Dates

Recommendation

This is a routine proxy filing detailing governance matters, executive compensation, and upcoming shareholder votes. It does not contain new financial results or significant strategic shifts that would warrant a 'buy' or 'sell' recommendation. The 'controlled company' status and the upcoming departure of the President and COO are noted, but without further context on their impact, a 'hold' recommendation is appropriate for a seasoned investor awaiting more substantive operational or financial updates.

Keywords

InnovAge Holding Corp., INNV, Proxy Statement, Annual Meeting, Board of Directors, Director Election, Auditor Ratification, Corporate Governance, Executive Compensation, SEC Filing, Healthcare Industry, PACE, Medicare, Medicaid, Risk Management, Shareholder Vote